Sun Pharma share price dips after US sales miss street

Sun Pharma share price slipped from intraday highs on Friday after the drug maker’s June quarter US sales and profit lagged market expectations, even as revenue and operating earnings grew year on year. The stock, which had hit a fresh 52 week high in the previous session, fell as much as 3 percent from the day’s peak after the results were released. Investors reacted to lower than expected US revenue of 427 million dollars and a net profit of ₹2,894 crore, both below street estimates.

According to NSE data, Sun Pharmaceutical Industries shares were recently trading around ₹1,992.2, down 0.4 percent from the previous close, after giving up early gains. The stock had climbed above ₹2,050 earlier in the session before reversing, with traders citing disappointment on the US business performance. On Thursday, the share price had crossed its earlier 52 week high of ₹1,993, touching about ₹1,996.9, and closed near ₹2,001.1. Sun Pharma’s market capitalisation stood at about ₹4.8 lakh crore, and the stock has delivered returns of nearly 12 percent over the past three months and about 16 percent so far in calendar 2026.

Stock Performance

Metric	Value
Close	₹1,992.2
Day Change	-0.4%
Intraday High	~₹2,050*
Intraday Low	Not stated
52-week High	₹1,996.9
52-week Low	Not stated
Market Cap	₹4,80,130.92 crore

*Intraday high approximated from trading range described in exchange data.

The immediate trigger for the Sun Pharma share price move was the company’s first quarter results, particularly the performance of its US business, which is a key driver of earnings. US sales came in at 427 million dollars for the June quarter, below street expectations that had pegged the figure in the 470 million to 480 million dollar range. Net profit at ₹2,894 crore missed a poll estimate of ₹3,051 crore, even though it was 27 percent higher than the ₹2,279 crore reported a year earlier. Revenue also undershot forecasts at ₹15,299 crore against expectations of about ₹15,625 crore, but still grew 10.5 percent from ₹13,851 crore in the same quarter last year.

Financial Performance

Metric	Current	YoY
Revenue	₹15,299 crore	+10.5%
EBITDA	₹4,417 crore	+3.0%
Net Profit	₹2,894 crore	+27.0%
EBITDA Margin	28.9%	Down from 31.0%

Despite the top line miss, Sun Pharma’s operating performance showed resilience. Earnings before interest, tax, depreciation and amortisation rose to ₹4,417 crore, ahead of street estimates of ₹4,255 crore and 3 percent higher than last year’s ₹4,302 crore. EBITDA margin expanded versus expectations, coming in at 28.9 percent compared with a forecast of 27.2 percent, although it was lower than the 31 percent margin recorded in the year ago quarter. The combination of better than expected margins and weaker than expected US sales left investors weighing the sustainability of profitability against growth in key markets.

The company did not immediately release detailed management commentary alongside the headline numbers, and there was no formal guidance update in the figures available. However, the margin outperformance suggests continued cost discipline and a favourable product mix in the quarter. At the same time, the shortfall in US revenue relative to market estimates pointed to a slower than anticipated ramp up in that geography, which typically commands higher margins and is closely watched by analysts.

Sun Pharma is India’s largest drug maker by market value, with a portfolio spanning branded generics, specialty products and over the counter medicines across domestic and international markets. The US business is a significant contributor to consolidated earnings, and expectations around that segment often influence the Sun Pharma share price on both NSE and BSE. The company has been a strong performer over the past few years, with three year returns of about 75.8 percent and five year gains of nearly 159 percent, according to exchange data. The recent move to fresh 52 week highs ahead of the results reflected optimistic positioning going into the quarter.

With the first quarter numbers now in, the next catalyst for the stock will likely be any detailed management commentary on the US business trajectory and margin outlook, as well as the subsequent quarterly results. Investors will also watch for further disclosures on dividends and any corporate actions, after the company highlighted its dividend history in recent updates. Until then, the Sun Pharma share price is expected to react primarily to evolving expectations around its US revenue recovery and the sustainability of its current margin profile.